HIV/AIDS Topics IAS 2015: International AIDS Society Conference Starts this Weekend in Vancouver
- Details
- Category: HIV Treatment
- Published on Wednesday, 15 July 2015 00:00
- Written by HIVandHepatitis.com
The 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2015) starts this Sunday and runs July 19-22 in Vancouver. HIV prevention -- including treatment-as-prevention and pre-exposure prophylaxis (PrEP) -- will be a major focus of the meeting. Other topics will include antiretroviral drugs in development, expanding access to treatment and retention in care, and HIV/hepatitis coinfection. HIVandHepatitis.com will be on site covering the latest news.
Drug Levels Are Key to Effectiveness of Tenofovir Vaginal Gel for HIV Prevention
- Details
- Category: Microbicides
- Published on Thursday, 09 July 2015 00:00
- Written by Liz Highleyman
Although the VOICE study failed to show an overall protective effect for tenofovir vaginal gel, further analysis suggests that women who had detectable blood drug levels were at lower risk of HIV infection, according to an analysis described in the June 29 advance edition of Journal of Infectious Diseases. Another recent analysis from the CAPRISA 004 trial showed that higher levels of tenofovir in the genital tract were associated with greater reduction in risk.
Coverage of the 2015 International AIDS Society Conference
- Details
- Category: HIV Treatment
- Published on Monday, 06 July 2015 00:00
- Written by HIVandHepatitis.com
HIVandHepatitis.com coverage of the International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2015), July 19-22, in Vancouver, Canada.
Conference highlights include HIV treatment as prevention, pre-exposure prophylaxis (PrEP), new antiretroviral therapies, HIV cure research, hepatitis C and HIV/HCV coinfection, and global scale-up of prevention and treatment.
7/22/15
Studies Advance Understanding of Broadly Neutralizing Antibodies Against HIV
- Details
- Category: HIV Vaccines
- Published on Thursday, 09 July 2015 00:00
- Written by Rockefeller University
Three recent studies funded by the National Institutes of Health have shed further light on broadly neutralizing antibodies that may play a role in developing an effective HIV vaccine. The studies demonstrated techniques for stimulating immune cells to produce antibodies that either could stop HIV from infecting human cells in the laboratory, or had the potential to evolve into such antibodies, according to a National Institute of Allergy and Infectious Diseases press release.
HIV-specific Immune Responses Linked to Reduced Infection Risk in PrEP Study
- Details
- Category: Pre-exposure Prophylaxis (PrEP)
- Published on Friday, 03 July 2015 00:00
- Written by George Washington University
People who remained HIV-negative in the iPrEx pre-exposure prophylaxis (PrEP) trial were more likely to show evidence of HIV-specific T-cell responses, and certain responses were significantly associated with reduced risk of infection, according to research published in the June 22 advance edition of Proceedings of the National Academy of Sciences. These findings suggest that natural immunity may be giving Truvada PrEP a boost in preventing HIV infection.
Web Design and Development by